James Galbraith, MD is an Associate Professor at the University of Alabama at Birmingham Emergency Medicine Department. Q: You have spent much of your career as an emergency medicine doctor and a researcher for Hepatitis C. What motivates you to do the work you do? A: I went into emergency medicine to deliver critical care,[…]
Judith Feinberg has a joint appointment in the West Virginia University School of Medicine as a professor of Behavioral Medicine & Psychiatry and Medicine/Infectious Diseases. She is the Vice Chair of the HIV Medicine Association and a nationally-recognized expert on the opioid epidemic in West Virginia, Appalachia and rural America. Q: The number of new[…]
Understand viral hepatitis where you live. On Hepatitis Testing Day be #HepAware and share our infographics with your networks.
Kate Moraras is the Senior Program Director at the Hepatitis B Foundation and the Director of Hep B United. Q: An estimated 20,900 people were newly diagnosed with acute Hepatitis B in 2016, but many Americans don’t even know that Hepatitis B is an issue. How do you address that knowledge gap and what do[…]
Thaddeus Pham is the Viral Hepatitis Prevention Coordinator at the Hawaii State Department of Health. Q: You were recently honored as one of the winners of the National Minority Quality Forum’s 40 Under 40 Leaders in Health. What drives your passion for healthcare and viral hepatitis in particular? Originally, I worked in HIV, where I[…]
Evelyn M. Foust, MPH, CPM, leads the Communicable Disease Branch in the North Carolina Division of Public Health at the Department of Health and Human Services. Heidi Swygard, MD, MPH, is a Clinical Associate Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina at Chapel Hill. Hepatitis C is[…]
Mark Sulkowski, MD is a Professor of Medicine at Johns Hopkins University. The advent of highly effective treatments for Hepatitis C represents remarkable scientific achievement marked by many important milestones including the recognition of non-A, non-B Hepatitis (1975); identification of the virus (1989); development of in vitro systems to study the virus and potential antiviral[…]
The other important component of the U.S. Hepatitis C epidemic is smaller in absolute numbers but is the major source of new Hepatitis C infections: infections associated with the opioid epidemic, injection drug use, and the sharing of needles and other drug injection equipment.
How is a curable disease still wreaking havoc on public health in this country? Why can’t we just treat and cure these people and make Hepatitis C a rare disease? The answers to these questions are complex, but those who work on Hepatitis C issues can agree on a key obstacle in achieving our goal of decreased Hepatitis C prevalence: we don’t invest enough in the prevention of Hepatitis C, or in the treatment of the disease.
New data featured on HepVu.org estimate about 3.9 million non-institutionalized people have had past or current Hepatitis C virus (HCV), and in 2010 an estimated 2.7 million had chronic HCV infections.